Search

You searched for "VEGF"

181 results found

RaScaL Study

1 June 2015 | | Retina / Uvea / Vitreous | Diabetic macular edema, Fluorescein angiography, Anti-VEGF, Ranibizumab, Laser photocoagulation, Combination therapy, Optical coherence tomography
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...

Oxford Handbook of Ophthalmology Third Edition

1 August 2015 | | Ophthalmology, Emergency Ophthalmology, Paediatric Ophthalmology / Strabismus, Neuro-Ophthalmology
The Oxford Handbook of Ophthalmology came out in 2006 and is now in its third edition. It is a valuable concise resource with over 1000 pages to cover initial assessment, diagnosis and management of a comprehensive range of ophthalmic problems....

Ophthalmology (third edition)

1 December 2018 | | Ophthalmology
If you are an ophthalmologist who enjoys books with coloured pictures, you’re no lone wolf. The third edition of Lang’s Ophthalmology will definitely pique your primal ophthalmologist instincts. You will be drawn to its soft-bound yet sturdy looking exterior. Flicking...
Seminars in Ophthalmology journal cover image

Treat-and-extend regimen in treatment of patients with type 3 neovascularisation

5 October 2020 | | Retina / Uvea / Vitreous
Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...

Cataract surgery in patients being treated for neovascular AMD

1 August 2018 | | Cataract and Refractive
This retrospective matched case control study evaluated outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age related macular degeneration (nAMD). They compared 124 patients that had cataract surgery with 372...

Steroid implants in the treatment of post-epiretinal membrane peel macular oedema

1 February 2018 | | Retina / Uvea / Vitreous | Central retinal thickness, Dexamethasone implant, Fluocinolone acetonide implant, Intravitreal steroid implants, Long-term outcome, Macular pucker surgery, Membrane peeling, Pars plana vitrectomy, Persistent macular edema
This is a retrospective review of 39 eyes of 37 patients treated with Ozurdex® (intravitreal dexamethasone implant) for persistent post-operative cystoid macular oedema (CMO) following vitrectomy and idiopathic epiretinal membrane (ERM) peeling. The 0.7mg implant was injected in each eye...

Outcomes of ‘treat and extend’ for neovascular AMD

1 August 2015 | | Retina / Uvea / Vitreous
The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...

Antibiotic prophylaxis after intravitreal injections

1 June 2014 | | Ophthalmology
The use of topical antibiotics as prophylaxis after intravitreal injections is a contentious issue, especially now with increasing use of intravitreal anti-VEGF agents. In the Wills Eye Institute, prior to May 2011, all patients undergoing intravitreal injections in the office...

New mouse model of diabetes mellitus

1 April 2014 | | Retina / Uvea / Vitreous | aldose reductase, cell signaling P-ERK1/2, P-SAPK/JNK, P-Akt, diabetic rats, diabetic retinopathy, green fluorescent proteins, growth factors VEGF, bFGF, TGF-β, retinal vascular changes, transgenic diabetic mouse models
Diabetic retinopathy (DR) is a serious complication of diabetes. It is driven by the loss of pericytes, cells which control vascular function, due to excess formation of sugar alcohols by the enzyme aldose reductase (AR). AR has been shown to...

Strategies for managing neovascular AMD and DMO in routine clinical care

1 October 2015 | | Retina / Uvea / Vitreous
Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...

My top five: Uses of artificial intelligence in ophthalmology

3 August 2023 | | Ophthalmology
Artificial Intelligence (AI) has emerged as a prominent topic of discussion within the field of ophthalmology, captivating researchers and practitioners alike. Although recent attention has been drawn to the integration of AI in ophthalmology, it’s important to recognise that AI...

Broadening of treatment options for potentially blinding retinal conditions

2 August 2022 | | Ophthalmology
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...